A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.

Researchers are continuing to explore how the CXCL13-to-BAFF ratio can be used to advance precision medicine for people with multiple sclerosis.

Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), likely contributing to the persistent inflammation characteristic of the ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUSTM ...

Fatigue is one of the most common and challenging symptoms for people living with primary-progressive and secondary-progressive multiple sclerosis (MS). It affects physical stamina, mental clarity, ...

The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...